Compare ING Groep NV (ING) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ING Groep NV vs TG Therapeutics Inc — how do they compare? ING Groep NV trades at $33.37 (market cap $93.76B), while TG Therapeutics Inc trades at $55.37 (market cap $8.16B). The key difference: ING Groep NV is far larger — about 11.5× TG Therapeutics Inc's market cap, and ING Groep NV pays a 3.95% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold ING Groep NV for 94 Days and TG Therapeutics Inc for 16 Days on average.
| ING | TGTX | |
|---|---|---|
Market Cap | $93.76B | $8.16B |
Volume | 4,620,220 | 1,735,121 |
Sector | Financials | Health |
52-Week High | $37.27 | $59.06 |
52-Week Low | $23.66 | $26.94 |
Typical Hold Time | 94 Days | 16 Days |
Enterprise Value | $236.48B | $8.37B |
Dividend Yield | 3.95% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ING stock trades at $33.43, down 1.44% with a bearish technical outlook. The company shows strong fundamentals with consistent earnings beats, a 28.34% net margin, and positive analyst sentiment (64.71% buy ratings). Recent news highlights management's raised ROE target to 16% for 2027 and upgraded revenue guidance, though cash flow trends remain negative.
The outlook is cautiously optimistic given strong profitability and growth initiatives, but risks include persistent negative cash flows and regulatory scrutiny in Australia. The stock presents value with a reasonable P/E of 12.86, supported by dividend payments and institutional confidence.
TG Therapeutics (TGTX) trades at $53.34, up 0.74% on the day, amid a bearish technical signal despite a neutral oscillator reading. The company reported strong revenue growth, with 2025 revenue at $616.29M and net income of $447.18M, though recent quarterly EPS misses and a negative net cash flow of $100.70M in 2025 highlight operational challenges. Positive news includes BRIUMVI capturing significant market share and institutional buying interest.
The outlook is mixed; robust analyst consensus (84.62% buy ratings) and a $80.50 price target suggest upside, but risks include ongoing litigation, earnings volatility, and high valuation multiples. Key catalysts are subcutaneous BRIUMVI data and potential acquisition interest, though execution risks remain.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About ING Groep NV
The merger of the Dutch postal bank and NN Insurance in 1991 created ING. Through a series of further acquisitions ING build up a global footprint. The 2008 financial crisis forced ING to seek government support--a precondition of which was that ING should separate its banking and insurance activities, which saw ING revert to being solely a bank. ING has market- leading banking operations in the Netherlands and Belgium, and a range of digital banks across Europe and Australia. Its global wholesale banking operation is primarily focused on lending.
Read more on ING →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
